An observational study in Progression and Survival, sponsored by Peking University People's Hospital. Status unknown at 1 site in China. Per ClinicalTrials.gov, last updated 2018-08-01.
Sponsored by Peking University People's Hospital · Observational
The expression level of PD-L1 on tumor cells is a pivotal point which might have some influence on prognosis, especially for those who might use PD-1 or PD-L1 antibody for treatment. The aim of this study is to detect the expression of PD-1 on advaced osteosarcoma patient who might use these antibodies for treatment. All those specimen should be taken by pathologist and confirmed with high tumor cellularity.
437 studies on the registry are indexed under Osteosarcoma; 116 are open to participants now.
This study's planned enrollment of 50 is below the median of 100 across 88 observational studies indexed under Osteosarcoma.
Browse Osteosarcoma studies →Peking University People's Hospital is the lead sponsor of 584 studies on the registry; 233 are open to participants now.
Counted across the registry records on this site, refreshed daily.
All those advanced osteosarcoma patients who intend to receive anti-PD-1/anti-PD-L1 therapy.
Exclusion Criteria:
All these patients who have been tested will be observed for further treatment and been recorded for toxicity.
Other: all study participants
patients will receive anti-PD-1/anti-PD-L1 antibody for further treatment
PD-L1 expression level
all those specimens will be tested for expression level,Tumors with ≥50% cells showing positive membrane staining were considered to have high expression of PD-L1
Time frame: 2 months
progression free survival
from the timing of testing to disease progression/death whichever comes first
Time frame: 2 years
overall survival
from the timing of testing to death/last follow-up
Time frame: 5 years
Plan to share: No
No publications or documents are linked to this record.
This study is status unknown, as verified in Jul 2018. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Peking University People's Hospital